Search clinical trials for: Estrogen Receptor Positive

Total 29807 results

Ain Shams University

Unknown

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT)

Metastatic Breast Cancer

Egypt
AstraZeneca

Completed

AZD9496 First Time in Patients Ascending Dose Study

ER+ HER2- Advanced Breast Cancer

United States, United Kingdom, Korea, Republic of
Novartis Pharmaceuticals

Terminated

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Cancer

United States, Canada
Swiss Group for Clinical Cancer Research

Completed

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Breast Cancer

Switzerland, Belgium
Helse Stavanger HF

Completed

Breast Cancer Diet Intervention Study (BCDIS)

Insulin Resistance | Estrogen Receptor-positive Breast Cancer | Early-stage Breast Cancer | Carbohydrate Engorgement | Proliferation
Dartmouth-Hitchcock Medical Center

Terminated

Phase I Study of the Combination of MLN9708 and Fulvestrant (Millennium)

Breast Cancer

United States
Danish Breast Cancer Cooperative Group
Novartis; Danish Cancer Society; The Danish Medical Research Council

Terminated

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer (REAL)

Operable Breast Neoplasms

Denmark
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Shaoguan University
Sun Yat-sen University

Completed

Anthocyanin Dose-escalation Study in Healthy Young Adults

Healthy

China
Mediclinic Middle East

Unknown

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation (Pembro)

Breast Cancer Female

United Arab Emirates
First Affiliated Hospital Xi'an Jiaotong University

Unknown

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer (PET)

Estrogen Receptor-positive Breast Cancer | Fulvestrant

China
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
National Nutrition and Food Technology Institute

Unknown

The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Metabolic Syndrome

Metabolic Syndrome

Iran, Islamic Republic of
National Cancer Institute (NCI)

Completed

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive

United States
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Completed

Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA)

Breast Cancer

United States, Canada
SOLTI Breast Cancer Research Group
Pierre Fabre Laboratories

Completed

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
Institute of Cancer Research, United Kingdom
Novartis; Cancer Research UK; Manchester University NHS Foundation Trust; University...

Active, not recruiting

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer (EPHOS-B)

Breast Cancer

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Ductal Carcinoma in Situ

United States
Seoul National University Hospital

Completed

Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

Korea, Republic of
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
University of Utah

Completed

Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance (POWER PIINC)

Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
National Cancer Institute (NCI)

Completed

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Withdrawn

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions
Sun Yat-sen University
AstraZeneca

Unknown

Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer (FANCY)

Breast Cancer

China
PrECOG, LLC.
Novartis

Completed

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (PrE0102)

Metastatic Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Male Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative

United States
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
Christiana Care Health Services

Completed

The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.

Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Breast Cancer

United States
Novartis Pharmaceuticals

Withdrawn

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

Breast Cancer
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer

Breast Cancer

United States
Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
ETOP IBCSG Partners Foundation

Completed

Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases (23-01)

Breast Cancer

France, Switzerland, Australia, Peru, Italy, New Zealand, Slovenia, Belgium, Brazil, Denmark
GlaxoSmithKline

Withdrawn

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Hormone-receptor Positive Breast Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Breast Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

Breast Cancer

United States
Masonic Cancer Center, University of Minnesota
Susan G. Komen Breast Cancer Foundation

Completed

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Breast Cancer | Fatigue | Neurotoxicity | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Long-term Effects Secondary to Cancer Therapy in Adults | Chemotherapeutic Agent Toxicity

United States
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
NanoString Technologies, Inc.

Completed

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Breast Cancer

United States
Western Regional Medical Center

Terminated

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy (ABC01)

Estrogen Receptor Positive Breast Cancer

United States
The Netherlands Cancer Institute

Terminated

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Breast Cancer

Netherlands

Search clinical trials for: Estrogen Receptor Positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations